Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The antidepressant, agomelatine, has a novel pharmacological profile, with agonist properties at M1 and M2 receptors and antagonist properties at 5HT2C receptors. Whether the antidepressant effects of this treatment are mediated by the drug's effects at the M1 and M2 receptors or the 5HT2C receptor or a synergy between these actions remains unclear. In the present study, a healthy volunteer model of emotional processing, which discriminates between effective and non-effective antidepressant compounds, was used to assess the contribution of melatonin agonism to the efficacy of agomelatine. Fifty-eight healthy volunteers were randomised to receive 7 days of once daily treatment with either 1 mg melatonin, 3 mg melatonin or placebo. Seven days treatment with 3 mg melatonin resulted in earlier bedtimes consistent with a phase advance in circadian rhythm. Some marginal effects of melatonin were observed on emotional processing; however, these were neither consistent with nor comparable to those seen following conventional antidepressant treatment or with agomelatine itself. These data suggest that the antidepressant action of agomelatine cannot be accounted for solely by its action at the M1 and M2 receptors.

Original publication

DOI

10.1177/0269881115592341

Type

Journal article

Journal

J Psychopharmacol

Publication Date

10/2015

Volume

29

Pages

1129 - 1132

Keywords

Agomelatine, depression, emotional processing, melatonin, Acetamides, Adolescent, Adult, Antidepressive Agents, Circadian Rhythm, Double-Blind Method, Emotions, Female, Healthy Volunteers, Humans, Male, Melatonin, Receptor, Melatonin, MT1, Receptor, Melatonin, MT2, Receptor, Serotonin, 5-HT2C, Serotonin 5-HT2 Receptor Antagonists, Young Adult